+30.4%
GSK vs ZCMD
-99.9%
+130.3%
-18.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | ZCMD | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | -3.8% | +1.8% | -1.9% |
| 7D | -1.8% | -8.0% | +6.2% | -1.9% |
| 30D | -2.2% | -27.9% | +25.7% | -2.2% |
| 3M | -1.8% | -74.6% | +72.8% | -1.2% |
| 6M | -10.6% | -99.5% | +88.8% | -9.8% |
| YTD | +4.4% | -99.7% | +104.2% | +5.2% |
| 1Y | +30.4% | -99.9% | +130.3% | +31.8% |
| All | +30.4% | -99.9% | +130.3% | +31.8% |
Cumulative growth
Daily Returns
Daily percentage return beside ZCMD.
Daily Out/Under-Performance
Portfolio return minus ZCMD return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × ZCMD return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded ZCMD wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling